174 related articles for article (PubMed ID: 27698203)
1. Blood Assay Predicts Response to Pembrolizumab.
Cancer Discov; 2016 Nov; 6(11):1200. PubMed ID: 27698203
[TBL] [Abstract][Full Text] [Related]
2. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
[No Abstract] [Full Text] [Related]
3. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.
Huang AC; Postow MA; Orlowski RJ; Mick R; Bengsch B; Manne S; Xu W; Harmon S; Giles JR; Wenz B; Adamow M; Kuk D; Panageas KS; Carrera C; Wong P; Quagliarello F; Wubbenhorst B; D'Andrea K; Pauken KE; Herati RS; Staupe RP; Schenkel JM; McGettigan S; Kothari S; George SM; Vonderheide RH; Amaravadi RK; Karakousis GC; Schuchter LM; Xu X; Nathanson KL; Wolchok JD; Gangadhar TC; Wherry EJ
Nature; 2017 May; 545(7652):60-65. PubMed ID: 28397821
[TBL] [Abstract][Full Text] [Related]
4. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.
Robert C; Ribas A; Wolchok JD; Hodi FS; Hamid O; Kefford R; Weber JS; Joshua AM; Hwu WJ; Gangadhar TC; Patnaik A; Dronca R; Zarour H; Joseph RW; Boasberg P; Chmielowski B; Mateus C; Postow MA; Gergich K; Elassaiss-Schaap J; Li XN; Iannone R; Ebbinghaus SW; Kang SP; Daud A
Lancet; 2014 Sep; 384(9948):1109-17. PubMed ID: 25034862
[TBL] [Abstract][Full Text] [Related]
5. Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies.
Bernard-Tessier A; Jeanville P; Champiat S; Lazarovici J; Voisin AL; Mateus C; Lambotte O; Annereau M; Michot JM
Eur J Cancer; 2017 Aug; 81():135-137. PubMed ID: 28624693
[No Abstract] [Full Text] [Related]
6. PD-1, CTLA-4 Point to Drug Response.
Cancer Discov; 2016 Nov; 6(11):1201. PubMed ID: 27655434
[TBL] [Abstract][Full Text] [Related]
7. A Rare Case of Pembrolizumab-Induced Uveitis in a Patient with Metastatic Melanoma.
Hanna KS
Pharmacotherapy; 2016 Nov; 36(11):e183-e188. PubMed ID: 27716999
[TBL] [Abstract][Full Text] [Related]
8. Personal response to immune checkpoint inhibitors of patients with advanced melanoma explained by a computational model of cellular immunity, tumor growth, and drug.
Perlstein D; Shlagman O; Kogan Y; Halevi-Tobias K; Yakobson A; Lazarev I; Agur Z
PLoS One; 2019; 14(12):e0226869. PubMed ID: 31877168
[TBL] [Abstract][Full Text] [Related]
9. [Pembrolizumab for the treatment of melanoma: updates and perspectives.].
Chiarion Sileni V; Mandalà M; Queirolo P
Recenti Prog Med; 2017 Dec; 108(12):528-531. PubMed ID: 29297903
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report.
Kwatra V; Karanth NV; Priyadarshana K; Charakidis M
J Med Case Rep; 2017 Mar; 11(1):73. PubMed ID: 28315636
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma.
Hersey P; Gowrishankar K
Future Oncol; 2015; 11(1):133-40. PubMed ID: 25572788
[TBL] [Abstract][Full Text] [Related]
13. Safety of pembrolizumab for the treatment of melanoma.
Martin-Liberal J; Kordbacheh T; Larkin J
Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Robert C; Schachter J; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank CU; Hamid O; Mateus C; Shapira-Frommer R; Kosh M; Zhou H; Ibrahim N; Ebbinghaus S; Ribas A;
N Engl J Med; 2015 Jun; 372(26):2521-32. PubMed ID: 25891173
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma.
Longoria TC; Tewari KS
Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1247-53. PubMed ID: 27485741
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab for the treatment of melanoma.
Kumar SS; McNeil CM
Expert Rev Clin Pharmacol; 2015; 8(5):515-27. PubMed ID: 26146011
[TBL] [Abstract][Full Text] [Related]
17. Checkpoint inhibition for advanced mucosal melanoma.
Thierauf J; Veit JA; Hess J; Treiber N; Lisson C; Weissinger SE; Bommer M; Hoffmann TK
Eur J Dermatol; 2017 Apr; 27(2):160-165. PubMed ID: 28174141
[TBL] [Abstract][Full Text] [Related]
18. Effective Response of Intrahepatic Cholangiocarcinoma to Pembrolizumab: A Case Report.
Nakamura M; Ueno M; Hayami S; Kawai M; Miyamoto A; Suzaki N; Hirono S; Okada KI; Miyazawa M; Kitahata Y; Kobayashi R; Kojima F; Yamaue H
Anticancer Res; 2020 Jul; 40(7):4123-4129. PubMed ID: 32620661
[TBL] [Abstract][Full Text] [Related]
19. Locally Advanced Unresectable Vaginal Melanoma: Response With Anti-Programmed Death Receptor 1.
Chanal J; Kramkimel N; Guegan S; Moguelet P; Fourchotte V; Avril MF
J Low Genit Tract Dis; 2016 Jan; 20(1):e4-5. PubMed ID: 26704337
[No Abstract] [Full Text] [Related]
20. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.
Ayers M; Lunceford J; Nebozhyn M; Murphy E; Loboda A; Kaufman DR; Albright A; Cheng JD; Kang SP; Shankaran V; Piha-Paul SA; Yearley J; Seiwert TY; Ribas A; McClanahan TK
J Clin Invest; 2017 Aug; 127(8):2930-2940. PubMed ID: 28650338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
